Your session is about to expire
← Back to Search
Neratinib plus TDxD for Stomach Cancer
Study Summary
This trial studies the safety/toxicity of Neratinib plus TDxD in patients with metastatic gastric cancer that are HER2-overexpressing. Those who failed prior chemo/HER2 therapy may be eligible.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had persistent diarrhea (more than 4 bowel movements per day) that hasn't improved with medical treatment and support in the two weeks before starting the therapy.You are taking medications or substances that can greatly affect the way Neratinib and/or TDxD work, so you cannot participate.You have had allergic reactions to drugs or substances similar to the ones used in this study.
- Group 1: Neratinib plus TDxD
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are investigators currently recruiting individuals for this trial?
"Per clinicaltrials.gov, this research is inviting volunteers to take part in the study. It was originally made available on June 24th 2022 and most recently updated 10 days ago (7/10/2023)."
What is the aggregate quantity of participants involved in this investigation?
"Affirmative. Clinicaltrials.gov illustrates that this clinical trial, which was first posted on June 24th 2022, is currently enrolling individuals. About 18 people need to be recruited from 1 facility."
Has the combination of Neratinib and TDxD been granted approval by federal regulators?
"Our research team at Power ranked Neratinib plus TDxD with a score of 1, as this is only in its initial phase of testing and has limited data attesting to its safety and efficacy."
Share this study with friends
Copy Link
Messenger